We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunohistochemistry as Effective as DNA Hybridization for Detecting ALK Rearrangement in Lung Cancer Patients

By LabMedica International staff writers
Posted on 08 Jul 2013
A team of Chinese researchers demonstrated that immunohistochemistry (IHC) provided a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of patients with non-small-cell lung cancer (NSCLC), in particular adenocarcinomas (ADCs), suitable for ALK-targeted therapy.

The ALK gene can be oncogenic in three ways: by forming a fusion gene with any of several other genes, by gaining additional gene copies, or with mutations of the actual DNA code for the gene itself. More...
The EML4-ALK (echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase) fusion gene is responsible for approximately 3%–5% of cases of NSCLC. The standard tests used to detect this gene in tumor samples is fluorescence in situ hybridization (FISH), and Reverse Transcriptase-PCR (RT-PCR). The FISH technique utilizes a DNA probe labeled with a fluorescent dye that is hybridized with target DNA, usually chromosome preparations on a microscopic slide. It is used to precisely map genes to a specific region of a chromosome in prepared karyotype, or can enumerate chromosomes, or can detect chromosomal deletions, translocations, or gene amplifications in cancer cells.

As IHC is a less complex and less costly technology than FISH, investigators at the Chinese University of Hong Kong SAR (China) evaluated its practical usefulness for detection of ALK rearrangement in NSCLC ADCs. They tested 373 lung ADCs for ALK rearrangement by IHC and FISH. Multiplex RT-PCR was performed to confirm the fusion variants.

Results showed that 22 of 373 lung ADCs (5.9%) were positive for ALK immunoreactivity. ALK-positive tumor cells demonstrated strong and diffused granular staining in the cytoplasm. All the ALK IHC-positive cases were confirmed to harbor ALK rearrangement, by either FISH, or RT-PCR. Two cases that were positive for ALK protein expression by IHC, but negative by FISH were shown to harbor EML4-ALK variant 1 by RT-PCR. None of the ALK IHC-negative cases was FISH-positive.

These results allowed the investigators to conclude that, "IHC can effectively detect ALK rearrangement in lung cancer. It might provide a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of suitable candidates for ALK-targeted therapy."

The study was published in the July 2013 issue of the Journal of Thoracic Oncology.

Related Links:
Chinese University of Hong Kong



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.